Nanobiotix Included in Euronext Tech Leaders Index
Biotechnology company Nanobiotix has been named to the Euronext Tech Leaders segment and index, which highlights Europe's leading high-growth technology companies. The inclusion aims to increase the company's visibility among international investors.
PARIS and CAMBRIDGE, Mass. – June 2, 2026 – Nanobiotix, a late-stage clinical biotechnology company pioneering nanotherapeutic approaches, announced its inclusion in the Euronext Tech Leaders segment and Index. This Euronext initiative is designed to enhance the visibility and attractiveness of Europe’s leading and high-growth technology firms to international investors.
"Our inclusion in the Euronext Tech Leaders segment recognizes not only the progress we have made as a company, but also the broader potential of physics-based innovation to contribute meaningfully to the future of healthcare," said Laurent Levy, chief executive officer of Nanobiotix. "We are honored to join this community of European innovators and look forward to continuing our mission of building new therapies designed to improve outcomes for millions of patients around the world." The Euronext Tech Leaders initiative, launched in 2022, brings together select companies recognized for their innovation, growth profile, and contribution to the European technology ecosystem. Membership provides companies with increased visibility among international investors and access to a network of market participants.
For Nanobiotix, joining the Euronext Tech Leaders segment reflects its position at the intersection of nanotechnology, physics, and medicine. The company is advancing physics-based nanotherapeutic platforms aimed at addressing significant unmet medical needs. Nanobiotix has been listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market since December 2020.